Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128136416> ?p ?o ?g. }
- W3128136416 endingPage "100700" @default.
- W3128136416 startingPage "100700" @default.
- W3128136416 abstract "Globally, trans people are disproportionately affected by HIV, but research on strategies to increase testing are limited. SELPHI is a randomised-controlled-trial (RCT) of 10,135 cis men, trans men, and trans women reporting lifetime anal intercourse with male partners (cis or trans), evaluating whether the offer of free HIV self-testing (HIVST) increases diagnosis. This subgroup analysis from the SELPHI RCT aims to describe key HIVST outcomes and HIVST acceptability for trans people.SELPHI recruited using social networking and trans focused social media. Participants were randomised 60/40 to baseline HIVST (Biosure™) (BT) vs no baseline HIVST (nBT); and at 3-months (if completed the survey and reported recent CAI) 50/50 to 3-monthly HIVST (RT) vs no repeat HIVST (nRT). Outcomes were self-reported through online surveys. We conducted a qualitative study of semi-structured peer-led participant interviews (n = 20) exploring HIVST motivations and experiences. These were analysed using a framework approach.SELPHI recruited and randomised 118 trans men and trans women (94 trans men, 24 trans women), of whom 20 (16 trans men, 4 trans women) underwent the second randomisation. Median age at baseline was 29 (IQR: 22, 37), 79% were white, 79% were UK born, 37% had degree level education, and 31% had never tested for HIV. 62% (n = 59) of trans men completed the 3-month survey, but survey completion by trans women in nBT was too low (1/11) for randomised comparison. In trans men HIV testing uptake by 3 months was significantly higher in BT (95% 36/38) vs nBT (29%, 6/21) (RR=3.32 (1.68, 6.55) p<0.001). Trans people randomised to RT reported 3 times higher rate of HIV testing compared to nRT during the two-year follow-up (IRR 3.66 (1.86, 8.01) p<0.0001). STI testing frequency (mean number of tests during each 13 week period/ 2-year follow-up) was not significantly different across interventions: RT (0.03) and nRT (0.01) (IRR=1.86 95%CI; 0.77, 5.15; p = 0.15). Social harms were rare. Acceptability was very high in BT: 97% (38/39) found instructions easy to understand, 97% (37/38) found the HIVST simple to use and 100% (39/39) reported good overall experience. In interviews, reported HIVST benefits included increased autonomy, privacy, convenience and avoidance of health care providers perceived to be discriminatory and services that increased dysphoria. Minor lancet and test processing issues were reported.HIVST significantly increased testing uptake and frequency in trans men and trans people overall, although recruitment and retention of trans women was low. HIVST acceptability was high and indicates easy access to this novel technology may increase HIV testing access for this key population." @default.
- W3128136416 created "2021-02-15" @default.
- W3128136416 creator A5004174170 @default.
- W3128136416 creator A5012263969 @default.
- W3128136416 creator A5017703523 @default.
- W3128136416 creator A5021925413 @default.
- W3128136416 creator A5031130805 @default.
- W3128136416 creator A5033016960 @default.
- W3128136416 creator A5033938755 @default.
- W3128136416 creator A5048403813 @default.
- W3128136416 creator A5053324673 @default.
- W3128136416 creator A5053823377 @default.
- W3128136416 creator A5057195076 @default.
- W3128136416 creator A5059392274 @default.
- W3128136416 creator A5067197153 @default.
- W3128136416 creator A5068239897 @default.
- W3128136416 creator A5081186229 @default.
- W3128136416 creator A5082320382 @default.
- W3128136416 creator A5085619123 @default.
- W3128136416 creator A5085719299 @default.
- W3128136416 creator A5087070007 @default.
- W3128136416 date "2021-02-01" @default.
- W3128136416 modified "2023-09-27" @default.
- W3128136416 title "Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales" @default.
- W3128136416 cites W1867823262 @default.
- W3128136416 cites W1964587597 @default.
- W3128136416 cites W2115046127 @default.
- W3128136416 cites W2138910933 @default.
- W3128136416 cites W2151997487 @default.
- W3128136416 cites W2168011889 @default.
- W3128136416 cites W2209048090 @default.
- W3128136416 cites W2293200518 @default.
- W3128136416 cites W2295284395 @default.
- W3128136416 cites W2346328222 @default.
- W3128136416 cites W2431906881 @default.
- W3128136416 cites W2444236768 @default.
- W3128136416 cites W2476945784 @default.
- W3128136416 cites W2483245862 @default.
- W3128136416 cites W2511440381 @default.
- W3128136416 cites W2540265316 @default.
- W3128136416 cites W2551421114 @default.
- W3128136416 cites W2561422706 @default.
- W3128136416 cites W2807772431 @default.
- W3128136416 cites W2889367364 @default.
- W3128136416 cites W2890985532 @default.
- W3128136416 cites W2897824461 @default.
- W3128136416 cites W2907570296 @default.
- W3128136416 cites W2916525824 @default.
- W3128136416 cites W2966569480 @default.
- W3128136416 cites W2982567237 @default.
- W3128136416 cites W2995030929 @default.
- W3128136416 cites W2995920015 @default.
- W3128136416 cites W2999597553 @default.
- W3128136416 cites W3048590185 @default.
- W3128136416 cites W3109229692 @default.
- W3128136416 doi "https://doi.org/10.1016/j.eclinm.2020.100700" @default.
- W3128136416 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7910695" @default.
- W3128136416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33681732" @default.
- W3128136416 hasPublicationYear "2021" @default.
- W3128136416 type Work @default.
- W3128136416 sameAs 3128136416 @default.
- W3128136416 citedByCount "13" @default.
- W3128136416 countsByYear W31281364162021 @default.
- W3128136416 countsByYear W31281364162022 @default.
- W3128136416 countsByYear W31281364162023 @default.
- W3128136416 crossrefType "journal-article" @default.
- W3128136416 hasAuthorship W3128136416A5004174170 @default.
- W3128136416 hasAuthorship W3128136416A5012263969 @default.
- W3128136416 hasAuthorship W3128136416A5017703523 @default.
- W3128136416 hasAuthorship W3128136416A5021925413 @default.
- W3128136416 hasAuthorship W3128136416A5031130805 @default.
- W3128136416 hasAuthorship W3128136416A5033016960 @default.
- W3128136416 hasAuthorship W3128136416A5033938755 @default.
- W3128136416 hasAuthorship W3128136416A5048403813 @default.
- W3128136416 hasAuthorship W3128136416A5053324673 @default.
- W3128136416 hasAuthorship W3128136416A5053823377 @default.
- W3128136416 hasAuthorship W3128136416A5057195076 @default.
- W3128136416 hasAuthorship W3128136416A5059392274 @default.
- W3128136416 hasAuthorship W3128136416A5067197153 @default.
- W3128136416 hasAuthorship W3128136416A5068239897 @default.
- W3128136416 hasAuthorship W3128136416A5081186229 @default.
- W3128136416 hasAuthorship W3128136416A5082320382 @default.
- W3128136416 hasAuthorship W3128136416A5085619123 @default.
- W3128136416 hasAuthorship W3128136416A5085719299 @default.
- W3128136416 hasAuthorship W3128136416A5087070007 @default.
- W3128136416 hasBestOaLocation W31281364161 @default.
- W3128136416 hasConcept C126322002 @default.
- W3128136416 hasConcept C144024400 @default.
- W3128136416 hasConcept C149923435 @default.
- W3128136416 hasConcept C168563851 @default.
- W3128136416 hasConcept C187960798 @default.
- W3128136416 hasConcept C3013748606 @default.
- W3128136416 hasConcept C44249647 @default.
- W3128136416 hasConcept C512399662 @default.
- W3128136416 hasConcept C71924100 @default.
- W3128136416 hasConceptScore W3128136416C126322002 @default.
- W3128136416 hasConceptScore W3128136416C144024400 @default.
- W3128136416 hasConceptScore W3128136416C149923435 @default.